shr-a1904
mAbexperimentalADC
Clinical trial activity
8 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
5
Phase 3
1
Phase 4
0
Earliest trial started Jul 1, 2021 (NCT04877717)
Timeline
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
- Payload
- Unclear
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07102901 | Phase 2 | Sep 5, 2025 | Hengrui Therapeutics, Inc. |
| NCT06881017 | Phase 2 | May 1, 2025 | China Medical University |
| NCT06649292 | Phase 3 | Nov 10, 2024 | Hengrui Therapeutics, Inc. |
| NCT06547736 | Phase 2 | Sep 30, 2024 | Fudan University, Hengrui Therapeutics, Inc. |
| NCT06350006 | Phase 1 | May 29, 2024 | Hengrui Therapeutics, Inc. |
| NCT05277168 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2022 | Hengrui Therapeutics, Inc. |
| NCT04928625 | Phase 1 | Aug 6, 2021 | Hengrui Therapeutics, Inc. |
| NCT04877717 | Phase 1 | Jul 1, 2021 | Hengrui Therapeutics, Inc. |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hengrui Therapeutics, Inc. | For profit | 7 | 6 | 3 | 2021 |
| China Medical University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2024 |
3 organizations
Page 1 / 1